In 2022 and 2023, significant advancements were made in non-invasive glycated hemoglobin (HbA1c) and blood glucose monitoring technology through government-supported R&D projects. The goal of this project was to develop an innovative prototype that allows users to measure their blood glucose levels anytime, anywhere without the need for blood sampling. This aimed to provide diabetes patients with a more efficient and affordable way to perform self-diagnosis and receive remote medical consultations.
In this project, new algorithms were developed for non-invasive measurement of HbA1c and blood glucose levels. By utilizing four models, including Beer-Lambert, Photon-Diffusion, Monte-Carlo Simulation, and machine learning algorithms, highly accurate data extraction was made possible. This enables real-time blood glucose monitoring through smartwatches and finger sensors (iFWatch, iFFinger), without the need for hospital visits or blood samples.
Additionally, the developed solution integrates wearable devices with a smartphone app and server to manage user data. It also connects with remote medical platforms, opening new possibilities for managing diabetes care.
This R&D project marks the world’s first introduction of non-invasive glycated hemoglobin measurement technology based on PPG signals, which is expected to significantly improve the quality of life for diabetes patients. Unlike traditional blood sampling methods, this new approach offers a low-cost, high-efficiency solution that has the potential to replace the existing market.
Key Achievements:
- Development of non-invasive glycated hemoglobin and blood glucose monitoring sensor modules
- Prototyping of finger-type and smartwatch-type devices (iFFinger, iFWatch)
- Development of an integrated software platform for self-diagnosis and remote medical consultations for diabetes patients
This project is expected to bring significant changes to diabetes care and serve as an important stepping stone for the commercialization of non-invasive blood glucose monitoring technology.
- Project Name: 2022 Corporate Research Institute R&D Capacity Enhancement Support Project
- Project Period: 2022.04.01.~2023.12.31. (Funds: $540,000.)
- Project Name: Development of a Prototype of a Biosensor-based Glycated Hemoglobin/Blood Sugar Measurement and Development of a Remote Care (Telemedicine) Platform
This research (project) was supported through the Korea Industrial Technology Association (KOITA) funded by the Ministry of Science and ICT (MSIT), Korea
RM#920, Gangnam ACE Tower, 174-10, Jagok-ro, Gangnam-gu, Seoul, 06373, Korea
QuickGly@KoreaIts.com 
82-2-2421-4022
In 2022 and 2023, significant advancements were made in non-invasive glycated hemoglobin (HbA1c) and blood glucose monitoring technology through government-supported R&D projects. The goal of this project was to develop an innovative prototype that allows users to measure their blood glucose levels anytime, anywhere without the need for blood sampling. This aimed to provide diabetes patients with a more efficient and affordable way to perform self-diagnosis and receive remote medical consultations.
In this project, new algorithms were developed for non-invasive measurement of HbA1c and blood glucose levels. By utilizing four models, including Beer-Lambert, Photon-Diffusion, Monte-Carlo Simulation, and machine learning algorithms, highly accurate data extraction was made possible. This enables real-time blood glucose monitoring through smartwatches and finger sensors (iFWatch, iFFinger), without the need for hospital visits or blood samples.
Additionally, the developed solution integrates wearable devices with a smartphone app and server to manage user data. It also connects with remote medical platforms, opening new possibilities for managing diabetes care.
This R&D project marks the world’s first introduction of non-invasive glycated hemoglobin measurement technology based on PPG signals, which is expected to significantly improve the quality of life for diabetes patients. Unlike traditional blood sampling methods, this new approach offers a low-cost, high-efficiency solution that has the potential to replace the existing market.
Key Achievements:
This project is expected to bring significant changes to diabetes care and serve as an important stepping stone for the commercialization of non-invasive blood glucose monitoring technology.
This research (project) was supported through the Korea Industrial Technology Association (KOITA) funded by the Ministry of Science and ICT (MSIT), Korea